<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05004831</url>
  </required_header>
  <id_info>
    <org_study_id>HMPL-013-FLAG-C106</org_study_id>
    <nct_id>NCT05004831</nct_id>
  </id_info>
  <brief_title>Fruquintinib Combined With TAS-102 in the Treatment of Patients With Advanced Metastatic CRC</brief_title>
  <official_title>Phase II Study of Fruquintinib Combined With TAS-102 in the Treatment of Patients With Advanced Metastatic CRC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II study aims to explore the efficacy and safety of fruquintinib combined with&#xD;
      TAS-102 in the third-line treatment of patients with advanced metastatic colorectal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, single center, one-arm phase II study. A total of 54 advanced mCRC&#xD;
      patients refractory to standard therapies will be enrolled and administered with fruquintinib&#xD;
      (4mg/d, qd po, D1-21, Q4W) combined with TAS-102 (70mg/m2/d, bid po, D1-5, 8-12, Q4W) until&#xD;
      intolerable toxicity, disease progression or death. Primary endpoint of this study is PFS and&#xD;
      secondary endpoints are OS, ORR, DCR and safety.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">September 2024</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS</measure>
    <time_frame>from randomization up to progressive disease or EOT due to any cause, up to 2 years</time_frame>
    <description>Progression-free Survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>from randomization until death due to any cause, assessed up to 3 years</time_frame>
    <description>Overall Survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR</measure>
    <time_frame>from randomization up to progressive disease or EOT due to any cause, up to 2 years</time_frame>
    <description>Disease Control Rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>from randomization up to progressive disease or EOT due to any cause, up to 2 years</time_frame>
    <description>Objective Response Rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerance</measure>
    <time_frame>from first dose to within 30 days after the last dose</time_frame>
    <description>Safety and tolerance evaluated by incidence, severity and outcomes of adverse events (AEs) and categorized by severity in accordance with the NCI CTC AE Version 5.0</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>fruquintinib plus TAS-102</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>fruquintinib plus TAS-102, orally given, Q4W</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fruquintinib plus TAS-102</intervention_name>
    <description>fruquintinib 4mg/d, qd po, D1-21, Q4W; TAS-102 70mg/m2/d, bid po, D1-5, 8-12, Q4W</description>
    <arm_group_label>fruquintinib plus TAS-102</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. ≥ 18 and ≤ 75 years of age;&#xD;
&#xD;
          2. Histological or cytological confirmed advanced metastatic colorectal cancer;&#xD;
&#xD;
          3. Refractory to at least second line standard treatment containing fluorouracil,&#xD;
             oxaliplatin and irinotecan;&#xD;
&#xD;
          4. At least one measurable lesion (larger than 10 mm in diameter by spiral CT scan or&#xD;
             20mm by conventional CT scan);&#xD;
&#xD;
          5. ECOG performance status of 0-1;&#xD;
&#xD;
          6. Life expectancy ≥ 12 weeks;&#xD;
&#xD;
          7. No previous treatment with vascular endothelial growth factor receptor (VEGFR)&#xD;
             inhibitor (TKI);&#xD;
&#xD;
          8. Signed and dated informed consent;&#xD;
&#xD;
          9. Adequate hepatic, renal, heart, and hematologic functions;&#xD;
&#xD;
         10. Willingness and ability to comply with scheduled visits, treatment plans, laboratory&#xD;
             tests, and other study procedure.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant or lactating women;&#xD;
&#xD;
          2. Any factors that influence the usage of oral administration or any disease or&#xD;
             condition that affects drug absorption;&#xD;
&#xD;
          3. Previous treatment with TAS-102;&#xD;
&#xD;
          4. Participated in clinical trials of other drugs within four weeks before enrollment;&#xD;
&#xD;
          5. Received other systemic anti-tumor therapy within 4 weeks before enrollment, including&#xD;
             chemotherapy, signal transduction inhibitors, hormone therapy and immunotherapy;&#xD;
&#xD;
          6. International normalized ratio (INR) &gt; 1.5 or partially activated prothrombin time&#xD;
             (APTT) &gt; 1.5 × ULN;&#xD;
&#xD;
          7. Clinically significant electrolyte abnormalities;&#xD;
&#xD;
          8. Subjected with hypertension that cannot be controlled by drugs, which is specified as:&#xD;
             systolic blood pressure ≥ 140 mmHg and / or diastolic blood pressure ≥ 90 mmHg;&#xD;
&#xD;
          9. Unrelieved toxic reactions higher than CTCAE V5.0 grade 1 caused by any previous&#xD;
             anti-cancer treatment;&#xD;
&#xD;
         10. Incomplete healing of skin wound, surgical site, traumatic site, severe mucosal ulcer&#xD;
             or fracture;&#xD;
&#xD;
         11. Conditions that may cause gastrointestinal bleeding and perforation determined by the&#xD;
             researcher;&#xD;
&#xD;
         12. History of arterial thrombosis or deep venous thrombosis within 6 months before&#xD;
             enrollment;&#xD;
&#xD;
         13. Stroke and / or transient cerebral ischemia occurred within 12 months before&#xD;
             enrollment;&#xD;
&#xD;
         14. Cardiovascular diseases with significant clinical significance;&#xD;
&#xD;
         15. LVEF&lt;50%;&#xD;
&#xD;
         16. Congestive heart failure New York Heart Association (NYHA) grade &gt; 2;&#xD;
&#xD;
         17. Evidence of CNS metastasis;&#xD;
&#xD;
         18. Previous treatment with VEGFR inhibition;&#xD;
&#xD;
         19. Ventricular arrhythmias requiring drug treatment;&#xD;
&#xD;
         20. Proteinuria ≥ 2+ (1.0g/24hr);&#xD;
&#xD;
         21. Coagulation dysfunction, hemorrhagic tendency or receiving anticoagulant therapy;&#xD;
&#xD;
         22. Other malignant tumors in the past 5 years, except skin basal cell or squamous cell&#xD;
             carcinoma after radical surgery, or cervical carcinoma in situ;&#xD;
&#xD;
         23. Active infection that is not controlled clinically, such as acute pneumonia, active&#xD;
             hepatitis B or hepatitis C;&#xD;
&#xD;
         24. By judgment of the investigator, there are concomitant diseases that seriously&#xD;
             endanger the safety of the patient or affect the completion of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jianjun Peng, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Affiliated Hospital, Sun Yat-Sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jianjun Peng, M.D.</last_name>
    <phone>+8613602263939</phone>
    <email>pjianj@mail.sysu.edu.cn</email>
  </overall_contact>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 6, 2021</study_first_submitted>
  <study_first_submitted_qc>August 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2021</study_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Peng Jian-jun</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

